University of Bolton Outlines Innovative New Measures for Students’ Safe Return to Campus in September
The University of Bolton will introduce a range of innovative measures to ensure it can reopen its campus safely for students and staff in September.
It has released an animated video starring cartoon character ‘LearnEd the Owl’ which outlines in detail how the campus will be made Covid-19 secure in time for the new academic year.
Measures will include:
- Installing sophisticated airport style walk through temperature scanners at every building entry.
- Making bicycles available for loan by students, enabling them to avoid crowded public transport.
- Providing on-campus bike parks as well as car parks.
- Providing regular socially distanced face-to-face tutorials, laboratory experience, access to arts studios and specialist facilities, etc.
- Implementing an effective scheduling system, limiting significantly the number of students on campus at any one time to keep everyone secure.
- Dividing sessions for access on campus into set times per day, for example, possibly between 8am-2pm and 2pm-8pm.
- Strictly observing recommended social distancing guidelines at all times.
- Ensuring there are adequate additional sanitiser stations.
- Making the wearing of face coverings on campus compulsory for the foreseeable future to safeguard everyone’s safety. In exceptional circumstances, such as misplacing or forgetting face coverings, students and staff will be issued with replacements.
- Carefully managed walking routes including one-way navigation.
- Multiple ‘learning zones’ being created across the campus, by identifying and transforming large spaces into areas featuring tables with plastic dividing screens to allow communication between people facing one another. (E.g. The ground floor of the National Centre for Motorsport Engineering will be cleared to become such a zone and other areas will also be repurposed).
- Additional self-service, café-style takeaway food and drink stations to minimise queues.
- Instigating a rigorous cleansing programme throughout all university buildings.
Work is now underway on the adaptations, which are being carried out with the involvement of key academic and support staff.
Professor George E Holmes, President and Vice Chancellor of the University of Bolton, said: “From September we will provide a COVID Secure working and learning environment for students and staff.
“Students will have access to a fully operational University campus and be able to study and engage in person with other students and staff.
“This will mean widespread changes to create a ‘new normal’ on campus and enable all students to physically attend the University campus safely at specified sessions.
“During those sessions they will be able to work in laboratories, studios and workshops, attend tutorials, meet other students or converse with their tutor, on top of continuing their learning online.”
Prof Holmes said: “I am determined that the University of Bolton is ahead of the game in transforming its campus to create a place where our students feel safe and happy and can make the most of their experience of Higher Education.
“The University student experience is not just about learning. Students want to see their friends in person, they want to engage with their tutors.
“Under our plans we can ensure they will be able to do this safely in September.”
The animated video outlining the University of Bolton safety measures under the ‘new normal’ can be watched at: https://youtu.be/yJKuGwVls7M
Notes to Editors:
Images (via We Transfer): Professor George E Holmes, President and Vice Chancellor of the University of Bolton; plus still images from the video and stock images of the UoB campus.
Tel: 07549 423245
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novaremed Announces IND Submitted to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy; Also Announces the Appointment of Three New Board Members25.5.2020 19:30:00 EEST | Press release
Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the novel drug candidate (NRD135S.E1) for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) to evaluate NRD135S.E1 in a Phase 2 study. Novaremed had received initial feedback from the FDA during a Pre-IND meeting held on July 24, 2019. The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients experiencing neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once daily for 3 months. “Submitting this IND is an important next step in the clinical development of NRD135S.E1 for the treatment of PDPN and we are moving rapidly to potentially address a global unmet medical need,” said Sara Mangialaio, M.D., Ph.D., CMO and Head of R&D at Novarem
Closer Collaboration between the EUIPO and EURid to Benefit SMEs25.5.2020 14:30:00 EEST | Press release
The European Union Intellectual Property Office (EUIPO) and EURid, the domain name registry for the .eu, .ею and .ευ top-level domains, are set to intensify collaboration to support trade mark and domain name applicants and owners, particularly small and medium enterprises (SMEs). This collaboration will support users of the EU IP system, particularly startups, by helping them to obtain trade mark and domain name protection in a joined-up manner, so they can secure their brands from the very beginning of their business journey. At present, EU trade mark applicants are advised whether their trade mark is available as a .eu domain name at the end of the online application process at EUIPO. Applicants and holders can also set up alerts to be informed once a .eu domain name that matches their trade mark is registered. Under a new work programme agreed jointly by the two organisations, the EUIPO and EURid will explore the possibility of implementing a reciprocal process when a .eu domain na
TIP Trailer Services Announces Appointment of New CFO25.5.2020 11:05:00 EEST | Press release
TIP Trailer Services, a portfolio company of I Squared Capital, has appointed Hans van Lierop as Chief Financial Officer and management board member. Hans started as CFO for TIP from Monday, 18th of May 2020 and is based in TIP’s international headquarters in Amsterdam, the Netherlands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005042/en/ Hans van Lierop, appointed CFO of TIP Trailer Services (Photo: Business Wire) “I am looking forward to joining TIP’s senior leadership team and leading its Finance organisation and look forward to contributing to TIPs future success. ” Hans van Lierop commented. Hans van Lierop joins TIP with broad international experience from different industries in Europe and Africa. He has held financial leadership roles in Diageo, Airtel and Massmart Walmart. Most recently, Hans Van Lierop was CFO of Massmart Walmart, a South African retail and wholesale distributor with a turnover of US$ 7
JEOL: Release of a New Schottky Field Emission Scanning Electron Microscope JSM-IT80025.5.2020 09:00:00 EEST | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200524005002/en/ JSM-IT800 (Photo: Business Wire) Development Background Scanning electron microscopes (SEMs) are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. As SEM applications are expanding from research and development to quality control and product inspection at manufacturing sites, SEM users are in need of faster high-quality data acquisition and simple compositional information confirmation with seamless operation. To meet these demands, the JSM-IT800, with the Intelligence Technology (IT) platform, incorporates our In-lens Schottky Plus field emission electron gun for high resolution imaging to fast elemental mapping, and an innovative electron optical cont
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine25.5.2020 09:00:00 EEST | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic. The fremanezumab data included pooled analyses of the AJOVY Phase 3 clinical trials (FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM)) which focused on the safety, efficacy and improved quality-of-life for patients experiencing difficult-to-treat migraine. Post-hoc analyses were also evaluated in patients who may experience challenges when managing their migraine due to comorbidities. Migraine creates a significant disease and economic burden. With more than one billion people impacted globallyi, migraine is the second leading global cause of years lived with disabilityii and annual costs of the disease in the U.S. and EU are $200 billio
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence23.5.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents the results of two patient surveys. The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections. The results show that over 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.1-4 “The results from these two important patient surveys provide significant insight into the real-life burden of the two conditions; however, they also highlight a worrying disconnect between patients’ treatment expectations and their actual experience. The findings, which build on our growing understanding of spasticity and cervical dystonia, provide us with the potential to unlock meaningful changes in clinical practice,” said Dr Alberto Esquenazi, Department of Physical Medicine
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom